If You Invested in Phathom Pharmaceuticals, Inc. (PHAT)

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases. According to the company’s public disclosures, Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada, and markets vonoprazan in the United States under the VOQUEZNA® brand family.

Core business and GI focus

Phathom’s business centers on acid-related GI disorders. The company describes itself as focused on developing and commercializing treatments for conditions such as gastroesophageal reflux disease (GERD), including Erosive GERD and Non-Erosive GERD, and Helicobacter pylori (H. pylori) infection in adults. Through VOQUEZNA, Phathom is active in both prescription GERD therapy and H. pylori eradication regimens.

Vonoprazan, the active ingredient in VOQUEZNA, is characterized by Phathom as an oral small-molecule PCAB that blocks acid secretion in the stomach. Company materials highlight vonoprazan’s acid-suppression profile and its use in clinical studies and approved indications related to GERD and H. pylori infection.

VOQUEZNA® product family

Phathom currently markets vonoprazan in the United States in several prescription presentations:

• VOQUEZNA® (vonoprazan) tablets for adults for:
  • Healing of all grades of Erosive Esophagitis (Erosive GERD) and relief of heartburn associated with Erosive GERD
  • Maintenance of healing of all grades of Erosive GERD and relief of associated heartburn
  • Relief of heartburn associated with Non-Erosive GERD
• VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults
• VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults

In its communications, Phathom notes that VOQUEZNA is approved in the U.S. for these adult indications and that vonoprazan is part of combination regimens for H. pylori infection. The company also reports that VOQUEZNA products have reached significant prescription volume in the U.S. market since launch, including milestones such as more than one million prescriptions dispensed for VOQUEZNA products in the United States since launch, as disclosed in its preliminary financial updates.

Clinical development and research programs

Beyond marketed products, Phathom is advancing clinical studies to expand the potential uses of vonoprazan. The company has announced a Phase 2 pHalcon-EoE-201 clinical trial evaluating VOQUEZNA (vonoprazan) tablets as an investigational treatment for eosinophilic esophagitis (EoE) in adults. This study is described as a two-part, randomized, double-blind, placebo-controlled trial enrolling adults with endoscopically confirmed EoE and dysphagia, with an extension phase in which all participants receive vonoprazan.

Phathom has also reported additional analyses from its pivotal Phase 3 pHalcon-NERD-301 trial in patients with Non-Erosive Reflux Disease (NERD). According to company disclosures and an article cited as published in the American Journal of Gastroenterology, VOQUEZNA improved nocturnal GERD symptoms in NERD patients, including measures such as heartburn-free nights and patient-reported outcomes related to nocturnal symptom severity and sleep-related impacts.

Regulatory and exclusivity profile

In its business updates, Phathom has discussed non-patent regulatory exclusivity for VOQUEZNA tablets and its expectations regarding the potential timing of generic entry, as well as the possibility that additional clinical programs, such as pediatric development, could support regulatory exclusivity. These statements are presented by the company as forward-looking and are subject to the risks and uncertainties described in its SEC filings.

Capital markets and Nasdaq listing

Phathom Pharmaceuticals, Inc. is listed on The Nasdaq Global Select Market under the ticker symbol PHAT, with its common stock registered pursuant to Section 12(b) of the Securities Exchange Act of 1934. The company has used underwritten public offerings of common stock and pre-funded warrants as a source of capital, including a public offering announced with expected gross proceeds of approximately $130 million, with stated use of proceeds for general corporate purposes, working capital, commercialization, and research and development expenses.

The company files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), including Form 8-K filings covering financial results, clinical and publication milestones, and leadership changes.

Leadership and corporate developments

Phathom has reported updates to its leadership team through SEC filings and press releases. For example, the company disclosed the appointment of a Chief Financial and Business Officer, along with details of that executive’s prior experience in commercial-stage biopharmaceutical companies and the key terms of the related employment agreement. These disclosures reflect Phathom’s emphasis on financial, commercial, and operational expertise to support its GI-focused growth strategy.

Safety and risk information related to VOQUEZNA

Company communications include detailed Important Safety Information for VOQUEZNA. VOQUEZNA (vonoprazan) is described as a PCAB indicated in adults for the healing and maintenance of healing of Erosive GERD and relief of associated heartburn, relief of heartburn associated with Non-Erosive GERD, and, in combination with amoxicillin or amoxicillin and clarithromycin, for the treatment of H. pylori infection.

Contraindications include known hypersensitivity to vonoprazan or any component of VOQUEZNA and concomitant use with rilpivirine-containing products. Warnings and precautions described by the company include considerations related to the presence of gastric malignancy, acute tubulointerstitial nephritis, Clostridioides difficile-associated diarrhea, bone fracture risk, severe cutaneous adverse reactions, vitamin B12 deficiency, hypomagnesemia and mineral metabolism, interactions with diagnostic investigations for neuroendocrine tumors, and fundic gland polyps. The company also lists adverse reactions observed in clinical studies across the approved indications and notes potential drug interactions, including with drugs dependent on gastric pH for absorption and certain CYP substrates.

Phathom’s materials further describe use considerations in specific populations, including recommendations regarding lactation, renal impairment, and hepatic impairment, and direct healthcare professionals and patients to the full Prescribing Information for comprehensive details.

Position within the GI treatment landscape

According to Phathom’s descriptions, VOQUEZNA represents a PCAB-based approach to acid suppression in contrast to traditional proton pump inhibitors (PPIs) and H2-receptor antagonists (H2RAs). The company highlights the prevalence and burden of GERD, particularly nighttime symptoms in Non-Erosive GERD, and notes that many patients continue to experience symptoms despite lifestyle interventions and existing therapies. Phathom’s clinical publications and press releases emphasize VOQUEZNA’s potential role in addressing these unmet needs, while also acknowledging that such statements are forward-looking and subject to clinical, regulatory, and commercial risks.

Summary

Overall, Phathom Pharmaceuticals, Inc. is presented in its public disclosures as a Nasdaq-listed biopharmaceutical company with a focused GI franchise built around vonoprazan and the VOQUEZNA brand family. Its activities span commercialization of approved therapies for GERD and H. pylori infection in adults, clinical development programs such as Phase 2 evaluation in eosinophilic esophagitis, publication of Phase 3 data in Non-Erosive GERD, and ongoing capital markets and corporate initiatives to support its GI-focused strategy.